Effect of cimetidine on survival after gastric cancer
| Autor: | Kaj Fischerman, Peter Hesselfeldt, Ulrich Knigge, Ole Julius Siemssen, P. M. Christiansen, Allan Hjortrup, Vilhelm Møller Pedersen, Hanne Tønnesen, Lars Bo Svendsen, Ib Krogh Pedersen, Steffen Bülow, Peter Damm |
|---|---|
| Rok vydání: | 1988 |
| Předmět: |
Adult
Male medicine.medical_specialty Every Three Months Denmark Placebo Gastroenterology law.invention Random Allocation Randomized controlled trial Double-Blind Method law Actuarial Analysis Stomach Neoplasms Internal medicine Medicine Humans Multicenter Studies as Topic Prospective Studies Cimetidine Prospective cohort study Aged Neoplasm Staging Retrospective Studies Aged 80 and over Clinical Trials as Topic Relative survival business.industry Cancer General Medicine Middle Aged medicine.disease Prognosis Clinical trial Anesthesia Drug Evaluation Female business medicine.drug |
| Zdroj: | Lancet (London, England). 2(8618) |
| ISSN: | 0140-6736 |
| Popis: | The effect of cimetidine on survival was investigated in 181 patients with gastric cancer. Immediately after operation or the decision not to operate, the patients were randomised in double-blind fashion to placebo or cimetidine 400 mg twice daily for two years or until death, with review every three months. Median survival in the cimetidine group was 450 days (range 1-1826) and in the placebo group 316 days (1-1653). The relative survival rates (cimetidine/placebo) were 45%/28% at 1 year, 22%/13% at 2 years, 13%/7% at 3 years, 9%/3% at 4 years, and 2%/0% at 5 years. Survival in the cimetidine group was significantly longer than in the placebo group. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|